Literature DB >> 10458753

CD8(+)NKR-P1A (+)T cells preferentially accumulate in human liver.

S Ishihara1, M Nieda, J Kitayama, T Osada, T Yabe, Y Ishikawa, H Nagawa, T Muto, T Juji.   

Abstract

A unique subset of T cells that co-express NKR-P1, which is a lectin type of NK receptor and is thought to have a major role in triggering NK activity, has been identified. In mice, NK1.1 (mouse NKR-P1C)(+) T cells, called NKT cells, preferentially accumulate in the liver and bone marrow. They predominantly use invariant Valpha14 chain TCR and phenotypically are CD4(+)CD8(-) or CD4(-)CD8(-) T cells. In this study, we analyzed, phenotypically and functionally, the NKR-P1A (analogue of murine NKR-P1C)(+) T cells resident in the human liver. Here, we show that in complete contrast to the NKT cells in the mouse liver, the majority of NKR-P1A(+) T cells in the human liver are CD8(+) and their TCR repertoire is not skewed to Valpha24 TCR, the homologue of murine Valpha14 TCR. Almost all of the NKR-P1A(+) T cells in the human liver expressed CD69, suggesting that they were activated. Furthermore, the NKR-P1A(+) T cells in the human liver exhibited strong cytotoxicity against a variety of tumor cell lines including K562, Molt4 and some colonic adenocarcinoma cell lines.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10458753     DOI: 10.1002/(SICI)1521-4141(199908)29:08<2406::AID-IMMU2406>3.0.CO;2-F

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  22 in total

Review 1.  Going both ways: immune regulation via CD1d-dependent NKT cells.

Authors:  Dale I Godfrey; Mitchell Kronenberg
Journal:  J Clin Invest       Date:  2004-11       Impact factor: 14.808

Review 2.  Immunology in the Clinic Review Series; focus on host responses: invariant natural killer T cell activation following transplantation.

Authors:  J-P Jukes; N D Jones
Journal:  Clin Exp Immunol       Date:  2012-01       Impact factor: 4.330

Review 3.  Clinical development of a novel CD1d-binding NKT cell ligand as a vaccine adjuvant.

Authors:  Neal N Padte; Xiangming Li; Moriya Tsuji; Sandhya Vasan
Journal:  Clin Immunol       Date:  2010-12-24       Impact factor: 3.969

4.  CD56+ T cells inhibit HIV-1 infection of macrophages.

Authors:  Wei Hou; Li Ye; Wen-Zhe Ho
Journal:  J Leukoc Biol       Date:  2012-05-16       Impact factor: 4.962

Review 5.  CD1d-restricted iNKT cells, the 'Swiss-Army knife' of the immune system.

Authors:  Jennifer L Matsuda; Thierry Mallevaey; James Scott-Browne; Laurent Gapin
Journal:  Curr Opin Immunol       Date:  2008-05-22       Impact factor: 7.486

6.  Ex vivo analysis of resident hepatic pro-inflammatory CD1d-reactive T cells and hepatocyte surface CD1d expression in hepatitis C.

Authors:  K Yanagisawa; S Yue; H J van der Vliet; R Wang; N Alatrakchi; L Golden-Mason; D Schuppan; M J Koziel; H R Rosen; M A Exley
Journal:  J Viral Hepat       Date:  2013-03-11       Impact factor: 3.728

7.  alpha -galactosylceramide-activated Valpha 14 natural killer T cells mediate protection against murine malaria.

Authors:  G Gonzalez-Aseguinolaza; C de Oliveira; M Tomaska; S Hong; O Bruna-Romero; T Nakayama; M Taniguchi; A Bendelac; L Van Kaer; Y Koezuka; M Tsuji
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-18       Impact factor: 11.205

8.  D-penicillamine-induced granulomatous hepatitis in brown Norway rats.

Authors:  Imir G Metushi; Xu Zhu; Jack Uetrecht
Journal:  Mol Cell Biochem       Date:  2014-04-27       Impact factor: 3.396

9.  Regulation of HLA-DR and co-stimulatory molecule expression on natural killer T cells by granulocyte-macrophage colony-stimulating factor.

Authors:  Kamal U Saikh; Teri Kissner; Robert G Ulrich
Journal:  Immunology       Date:  2002-07       Impact factor: 7.397

10.  CD161+ T (NT) cells exist predominantly in human intestinal epithelium as well as in liver.

Authors:  T Iiai; H Watanabe; T Suda; H Okamoto; T Abo; K Hatakeyama
Journal:  Clin Exp Immunol       Date:  2002-07       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.